NCT03840967View on ClinicalTrials.gov

A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 9, 2019

Primary Completion Date

November 17, 2022

Study Completion Date

February 22, 2023

Conditions
Esophageal CancerGastric CancerAdenocarcinoma
Interventions
DRUG

Niraparib

Niraparib will be administered as a flat-fixed daily dose depending on weight and platelet count. Subjects will take orally on a daily basis for 28 days. Each cycle = 28 days

Trial Locations (4)

14263

Roswell Park Cancer Institute, Buffalo

33612

Moffitt Cancer Center, Tampa

46202

Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis

48109

University of Michigan Health System, Ann Arbor

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Indiana University School of Medicine

OTHER

lead

Shadia Jalal, MD

OTHER